Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Cumberland Pharmaceuticals Inc (CPIX)
Price$6.79Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.5M | $37.9M | $39.6M | $42.0M | $35.0M | $35.8M | $32.4M | $28.8M | $40.4M | $32.5M | $900,000 | $600,000 | $800,000 | $700,000 | $51.1M | $45.9M | $43.5M |
| Gross profit | $37.9M | $31.3M | $33.5M | $32.9M | $26.2M | $27.2M | $25.0M | $22.8M | $33.0M | $26.5M | −$4.1M | −$4.5M | −$4.6M | −$4.3M | $45.8M | $42.3M | $39.4M |
| Gross margin | 85.02% | 82.61% | 84.66% | 78.29% | 74.86% | 75.86% | 77.10% | 79.11% | 81.75% | 81.65% | −452.02% | −742.19% | −579.93% | −620.88% | 89.51% | 92.18% | 90.50% |
| Research & development | $5.6M | $4.8M | $5.8M | $6.7M | $5.7M | $5.8M | $6.9M | $7.6M | $4.3M | $3.2M | $3.8M | $3.4M | $5.6M | $5.1M | $5.0M | $4.3M | $5.0M |
| Operating expenses | $47.3M | $44.3M | $49.1M | $47.7M | $33.9M | $33.6M | $34.3M | $34.0M | $37.1M | $28.0M | — | — | — | — | $41.3M | $39.4M | $37.8M |
| Operating income | −$2.8M | −$6.4M | −$9.6M | −$5.7M | −$7.7M | −$6.4M | −$9.3M | −$11.2M | −$4.1M | −$1.4M | $1.1M | $3.6M | −$3.8M | $8.8M | $9.8M | $6.5M | $5.8M |
| Operating margin | −6.27% | −16.99% | −24.16% | −13.58% | −21.91% | −17.81% | −28.66% | −38.79% | −10.11% | −4.41% | 123.51% | 593.14% | −475.17% | 1,259.73% | 19.26% | 14.17% | 13.27% |
| EBITDA | $1.4M | −$1.5M | −$4.6M | −$376,816 | −$3.1M | −$1.6M | −$4.9M | −$8.2M | −$1.4M | $963,777 | $3.4M | $5.5M | −$2.5M | $9.7M | $10.9M | $7.5M | $6.6M |
| EBITDA margin | 3.04% | −4.04% | −11.68% | −0.90% | −8.76% | −4.56% | −15.07% | −28.43% | −3.55% | 2.97% | 373.16% | 924.73% | −312.44% | 1,388.54% | 21.29% | 16.31% | 15.14% |
| Net income | −$2.8M | −$6.5M | −$6.3M | −$5.6M | −$3.5M | −$3.3M | −$3.5M | −$7.0M | −$8.0M | −$944,683 | $731,351 | $2.4M | −$2.1M | $5.8M | $5.7M | $2.5M | $3.1M |
| Net profit margin | −6.37% | −17.11% | −15.88% | −13.26% | −10.01% | −9.32% | −10.92% | −24.17% | −19.76% | −2.91% | 81.26% | 403.95% | −263.08% | 834.64% | 11.06% | 5.36% | 7.10% |
| Basic EPSper basic share | -$0.19 | -$0.46 | -$0.44 | -$0.38 | -$0.24 | -$0.22 | -$0.23 | -$0.45 | -$0.50 | -$0.06 | $0.04 | $0.14 | -$0.11 | $0.30 | $0.28 | $0.12 | $0.22 |
| Diluted EPSper diluted share | -$0.19 | -$0.46 | -$0.44 | -$0.38 | -$0.24 | -$0.22 | -$0.23 | -$0.45 | -$0.50 | -$0.06 | $0.04 | $0.14 | -$0.11 | $0.30 | $0.28 | $0.12 | $0.17 |
Owners
Reported shareholders
≈38.01%of listed shares
KAZIMI A J5.7M shares · Mar 16, 2026
View holders
| Holder | % owned |
|---|---|
KAZIMI A J | ≈38.01%5.7M shares |
Ikarian Capital, LLC | 3.36%503.15K shares |
RENAISSANCE TECHNOLOGIES LLC | 3.19%478.26K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.53%379.48K shares |
Krogulski Kenneth | ≈2.02%302.34K shares |
DIMENSIONAL FUND ADVISORS LP | 1.56%233.31K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 0.75%112.54K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.72%108.41K shares |
PERCEPTIVE ADVISORS LLC | 0.65%96.98K shares |
CITADEL ADVISORS LLC | 0.49%73.39K shares |
Galante Joseph C | ≈0.42%63.66K shares |
BlackRock, Inc. | 0.42%63.55K shares |
Bank of New York Mellon Corp | 0.39%58.46K shares |
JANE STREET GROUP, LLC | 0.38%56.74K shares |
VANGUARD FIDUCIARY TRUST CO | 0.37%54.91K shares |
Jones James | ≈0.31%46.86K shares |
STATE STREET CORP | 0.26%39.51K shares |
Young Caroline | ≈0.23%35.11K shares |
UBS Group AG | 0.18%26.34K shares |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.17%26.2K shares |
Percentages use 14.98M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 29, 2025Form 4 · 10b5-1 | Young CarolineDirector | BuyCommon Stock | 6 | $3.45 | $20.70 | 32.9K |
| Aug 29, 2025Form 4 · 10b5-1 | Jones JamesDirector | BuyCommon Stock | 13 | $3.45 | $44.85 | 43.9K |
| Aug 29, 2025Form 4 · 10b5-1 | KAZIMI A JChairman and CEO | BuyCommon Stock | 13 | $3.45 | $44.85 | 5.70M |
| Aug 29, 2025Form 4 · 10b5-1 | Krogulski KennethDirector | BuyCommon Stock | 68 | $3.45 | $234.60 | 289.7K |
| Aug 28, 2025Form 4 · 10b5-1 | Young CarolineDirector | BuyCommon Stock | 6 | $3.47 | $20.82 | 32.9K |